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Objectives: Bronchiectasis (BE) is characterised by permanent dilation of bronchi 
with destruction of elastic and muscular components of their walls. Prophylactic 
antibiotic treatment with acute management of exacerbation episodes is an impor-
tant component of treatment. Currently there are no approved therapies for BE 
and inhaled antibiotics and nebulized solutions are used off-label. The objective 
of this study was to predict clinical and economic consequences associated with 
BE in adult patients over their lifetime. MethOds: We developed a Markov cohort 
model with a cycle length of 4 weeks from UK health care perspective. The model 
included 4 Markov states: one stable disease state defined as confirmed non - cystic 
fibrosis bronchiectasis and without exacerbations in the previous 4 weeks and three 
exacerbation states defined on the basis of severity of exacerbation and associated 
health care resource utilization. Disease state specific costs included costs of drugs, 
consultations/visits, diagnostic test/procedures, physiotherapy, emergency room 
visits and hospitalizations. Patient baseline characteristics, exacerbation rates and 
utilities were estimated from literature. Results: The model suggests that ability to 
reduce hospitalizations and limit impact on quality of life are the major value driv-
ers. The model is also sensitive to baseline risk of exacerbations. A treatment for BE 
that results in 35% reduction in exacerbation rates and related hospitalizations may 
result in a reduction of 15.53 exacerbations and 3.23 hospitalizations per patient 
over lifetime. Reduction in number of hospitalization will result in fewer long-term 
complications, leading to reduction of 1 death per 600 patients over a period of 10 
years. The treatment could result in reduction of medical cost by £10,777 and 0.11 
QALY gain per patient over lifetime. cOnclusiOns: Any health care intervention 
that could reduce the number of exacerbations and related hospitalizations in the 
BE patients can have significant beneficial impact on clinical outcomes, costs and 
quality of life.
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Objectives: Since treatment with biologics may reactivate latent TB, testing and 
prophylaxes before initiating therapy are mandatory. However, there is not a unique 
solution for the number and type of tests to be used for detecting the presence of TB, 
and for the definition of when prophylaxis should be prescribed. Which alternative 
should be preferred depends on the effectiveness of treatment and also on the cost 
associated. This methodological study aims to define a general economic model to 
assess different protocols for latent TB detection in patients undergoing anti-TNF 
treatment. MethOds: A decision tree approach has been designed for comparing 
alternative protocols in terms of (a) expected costs of different strategies for latent 
TB assessment in patients undergoing anti-TNF treatment; b) the economic conveni-
ence of the prophylaxis therapy in presence of a negative chest X-ray. Uncertainty is 
expressed by the probability of being positive and negative to the tests. In the NHS 
perspective the model considers: costs of tests; costs of TB onsets for rheumato-
logic patients who undergo biologics; costs of extending anti TB prophylaxis also 
to false negative patients; costs related to 1-month biologic therapy delay because 
of prophylaxis; costs for adverse events therapy and/or test related. Indirect costs 
are also considered in the broader societal perspective. Results: Costs assessed 
are useful to choose the less costly alternatives. The comparison also considers 
the reduction of false negatives to the tests which do not follow prophylaxis while 
being affected by latent TB. cOnclusiOns: The model, that can represent a useful 
tool both for clinical and health policy decision making, is a general one; it can be 
applied to any country by inserting the country specific epidemiological, clinical, 
and economical data, and to any anti-TNF drug, by using the specific biologic drug-
related risk factor.
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Objectives: The aim of this study is to assess how cost-effectiveness analyses of 
personalized medicine approaches (PMA) can be efficiently designed by using a 
case study in the field of acute myeloid leukemia. MethOds: The cost-effective-
ness analysis of the PMA was performed in two steps. As a PMA often only causes a 
treatment change in a specified subgroup of the patients, the cost-effectiveness of 
the identified treatment change was estimated as a first step (restricted analyses). 
Subsequently, a full cost-effectiveness analysis was performed which included 
all patients and the costs of identifying the specified subgroup. The relation-
ship between the full and restricted analyses was evaluated by varying different 
input parameters. Results: It was found that the full cost-effectiveness of a 
PMA approach could be described as a function of the (cost-) effectiveness of the 
treatment change in the specified subgroup, the costs of identifying the subgroup 
and the size of the subgroup. If no additional costs are associated with the iden-
tification of the subgroup, the incremental cost-effectiveness ratio (ICER) of the 
full analysis is identical to the ICER of the restricted analysis. Otherwise, the ICER 
Objectives: Diabetic nephropathy (DN) is a progressive kidney disease that occurs 
in around 40% of patients with diabetes, and the recommended treatment is an 
angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker 
(ARB). Individuals’ health-related quality of life (HRQoL) can be summarised by 
utility values, which reflect preferences for different health states, and are used in 
cost-utility analyses (CUAs). This literature review identified the utilities used in 
CUAs of ACEi/ARB treatment in patients with DN. MethOds: A combined protocol 
was developed to identify CUAs of ACEi/ARB treatment in DN as well as studies 
that estimated utilities in DN (for a separate review). We searched electronic data-
bases (MEDLINE, EMBASE, NHS EED, HEED, CEA Registry, EconLit, RePEc, HTA) from 
1 January 2000 to 31 July 2013. Search results were assessed for relevance by two 
reviewers. For eligible CUAs, data extracted included health states with assigned 
utilities. Results: Of 5236 references identified from the combined search, 28 CUAs 
remained after review of titles/abstracts, and eight after full text review. The CUAs 
assessed treatment (ACEi n= 3; ARB n= 4; both n= 1) in patients with type 1 diabe-
tes (n= 2), type 2 diabetes (n= 4) or unspecified diabetes (n= 2). Seven CUAs used a 
Markov model and one a decision-analysis tree. Health states in the models included 
microalbuminuria, proteinuria, nephropathy, end-stage renal disease (ESRD), non-
ESRD, dialysis and transplant. ESRD was the most frequent, with utilities ranging 
0.53-0.69 (n= 6). Utility data used in the models were sourced from a number of 
different studies. cOnclusiOns: For CUAs of ACEi/ARB therapy in patients with 
DN, few health states were included, and there was variation in values for the same 
health state due to a range of different reference sources being used. It is important 
for future economic models of DN therapies that robust utility values are available 
for included health states.
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Objectives: The main objective of this study is to estimate the impact of the level 
of functional status and disability on health service costs related to rheumatoid 
arthritis (RA) disease in Hungary. It is straightforward to think that higher disability 
implies higher costs, where the nature of the relationship is unclear. In order to 
explore the dependence structure a novel approach is proposed. Instead of fitting 
trend lines for the cost by regression methods the entire bivariate distribution was 
modelled. MethOds: Health Assessment Questionnaire’s disability index data 
were collected for 497 RA patients (with 2594 observations) treated in the Arthritis 
Center (AC) Buda Hospital of Hospitaller Brothers of St. John from 1st January 2005 
to 31st July 2013. The same patients were also found in the database of National 
Health Insurance Fund Administration (NHIFA) and further parameters as e.g. 
relevant treatments and health service costs (in- and outpatient) were collected. 
After merging AC and NHIFA database the 2 dimensional patterns of the HAQ-
index measurements versus costs (sum of relevant costs in the following quarter 
year) become available for bivariate modelling. The ingredients were the empiri-
cal distribution of HAQ-index and quarter year cost, and some parametric copula 
families (elliptical or Archimedean) capturing the (possibly non-linear) dependence 
structure. The performance of the different model assumptions were compared by 
goodness-of-fit procedures. Results: The fitted bivariate distribution based on 
the best-performing dependence model are shown in the original “HAQ-index vs. 
cost” scale. The differences of average costs for low/medium/high HAQ-index values 
are summarized and the conditional distribution functions of costs are presented, 
respectively. cOnclusiOns: It has been proved that there is a significant posi-
tive dependence between the disability status of RA and health service costs. The 
dependence cannot be considered as linear but this non-linearity can be tackled 
easily by using copula methods.
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Objectives: To design a user-friendly cost calculator to estimate and project 
health care costs of patients diagnosed with hepatitis C virus (HCV) infection in 
Turkey. MethOds: We used Visual Basic in a Microsoft Excel to program compli-
cated models within an easy-to-use framework for providers and payers to calculate 
pharmacy costs for HCV patients in Turkey. The calculator, first, uses the starting 
year to the end year as an input. The user then enters prevalent and incident patient 
numbers. Medication types, medication names, prescription numbers per year and 
prescription costs per medication are also entered. The calculator allows combina-
tion therapies. Depending on response rates, rates of incident and prevalent patients 
and medications type, prescription rates from 2014 and forward (until 2020) can 
then be calculated and projected. The calculator can be used for any country as 
long as the inputs are available through literature from real-world or simulation 
studies. Results: We used a hypothetical example to project pharmacy costs in 
Turkey in 2014 and 2015. We assumed 10,000 patients in 2014 (20% were assumed to 
be treatment naïve) and expected 2,000 new patients in 2015. We assumed ribavirin 
and telaprevir combination therapy for 2014 treatment naïve patients, and peginter-
feron alfa-2a and ribavirin for prevalent patients. The response and treatment rates 
were assumed at 80% for patients who were eligible for treatment. The recurrence 
rate was assumed to be approximately 10% after treatment. Pharmacy costs for HCV 
were calculated at € 7 million in 2014 and approximately € 2 million in 2015, using 
these rates. cOnclusiOns: The economic burden of HCV in Turkey is significant. 
A simple-to-use calculator that uses real-world data and econometric models to 
estimate health care costs of patients with HCV can help payers and providers to 
make improved evidence-based health care decisions.
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across every stage, all of which are fully transparent, provides a unique combination 
of broadness, resilience and inclusiveness making it an ideal decision making tool.
PRM53
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Objectives: Many aspects of QALY measurement in children are not yet fully 
developed. This study is aimed at contextualizing the mapping methodology 
in a field not yet covered: paediatric asthma. The objective is to derive utility 
values from non-preference-based questionnaires, the estimated utility values 
will be useful for QALY assessment by means of: i) evaluation of a linear map-
ping between the generic preference-based EQ-5D-3L (self- and proxy-versions) 
and the condition-specific non-preference-based Paediatric Asthma Quality of 
Life Questionnaire (PAQLQ) and Paediatric Asthma Caregiver’s Quality of Life 
Questionnaire (PACQLQ), respectively; ii) assessment of the capability of map-
ping to discriminate for disease severity. MethOds: Either PAQLQ or PACQLQ and 
EQ-5D-3L will be administrated to 170 asthma children (7-17 years of age) during 
a 24-month multicenter randomized placebo-controlled trial of allergen specific 
sublingual immunotherapy coded EudraCT No. 2012-005678-76/FARM94793N at 
baseline, month 12, and month 24 visits. Level of severity will be assessed using 
the Asthma Control Test (ACT) and the Childhood-ACT (C-ACT) questionnaires. 
The possibility of a linear mapping will be evaluated through a Tobit model, where 
either PAQLQ/PACQLQ will be tested as predictors of EQ-5D-3L answers. Capability 
of mapping to be sensible in changes of disease severity will be measured 
through a Pearson’s correlation between changes in estimated EQ-5D-3L scores 
and changes in ACT and C-ACT answers. Results: Linear mapping, if feasible, 
applies the statistical relationship between either PAQLQ or PACQLQ and EQ-5D-3L, 
being PAQLQ/PACQLQ answers predictors of EQ-5D-3L score. EQ-5D-3L and PAQLQ/
PACQLQ, as well as EQ-5D-3L built on PAQLQ/PACQLQ answers by applying the 
linear mapping is expected to discriminate for both patients’ level and changes 
in disease severity. cOnclusiOns: This study seeks to inform policy makers in 
their choice of the source of utility values and their discrimination across severity 
groups and responsiveness in asthma children.
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Objectives: Guidelines for economic evaluation from ISPOR and NICE recom-
mend the use of mean values rather than medians, but do not offer guidance for 
situations when mean values are not available. This study evaluated the impact 
of different methods of estimating means from medians, within the context of 
estimating treatment duration for drugs used to treat mCRC. MethOds: Clinical 
trials and prescribing information for drugs used to treat mCRC were reviewed 
for information on the mean, median, and range of treatment cycles. Various 
approaches were used to estimate mean values, including direct use of the median, 
a published equation considering the median and range, confidence intervals and 
interquartile range, and the use of distributions commonly used in survival analy-
sis. Where possible, the estimated means were compared with reported means 
from clinical trials. Results: Very few studies reported both median and mean 
treatment duration; direct use of the median under-predicted the mean by 23-39% 
and the published equation over-predicted the mean by 19-28%. Simple assump-
tions about the distribution of treatment durations performed best, predicting the 
reported mean within ±12%. The use of progression-free survival as a proxy for 
treatment duration over-predicted treatment duration by 5-38%, although esti-
mates were improved by accounting for early discontinuation. cOnclusiOns: 
By only considering the 50th percentile, the median may not provide an accurate 
representation of the outcomes in a population. It is important that researchers 
and budget-holders are aware of the limitations in the use of medians, and that 
they consider multiple estimation methods to estimate mean values for economic 
analyses.
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Objectives: Prostate cancer (PCa) incidence has been steadily increasing over the 
last twenty years, resulting in Ireland having the highest incidence rate in Europe 
in 2008. The main driver of this is wide-spread use of prostate specific antigen 
(PSA) testing in primary care as an ad-hoc detection mechanism. The objective of 
this research was to undertake a cost-effectiveness analysis of organised screening 
using PSA testing in Ireland. MethOds: Using a Bayesian Multi-Parameter Evidence 
Synthesis (MPES) framework, non-cost parameters were synthesised, informed by 
incidence, mortality and clinical data from the National Cancer Registry Ireland 
for men diagnosed with PCa in 2009. The MPES framework estimates unobserved 
parameters using available evidence and so facilitates analysis of interventions 
where observational data is limited. Average costs were estimated using project-
specific survey costs, Irish hospital costs (HSE Casemix) and costs published in the 
literature. Effectiveness of PSA testing was sourced from the literature. Utility scores 
were collected from 2,500 PCa survivors. The cost-effectiveness analysis employed 
a cohort, semi-Markov model following men from age 30 to death. A range of PSA 
screening strategies were compared with no PSA testing and an extensive series of 
increases with higher test costs, smaller subgroup and smaller incremental effects 
due to the treatment change. cOnclusiOns: The data collection of costs, survival 
and quality of life of PMAs should be restricted to the subgroup for whom treat-
ment changes. Therefore, cost-effectiveness analyses of PMAs should start with 
identifying that subgroup. Once the size of the subgroup, the cost-effectiveness 
of the treatment change and the test costs are known, the full cost-effectiveness 
can be easily calculated. The described function can also be used to assess the 
potential cost-effectiveness of future PMAs. If a PMA causes a treatment change 
in a small subgroup, the PMA can only be cost-effective with low test costs or 
large incremental effects.
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Objectives: Health economic evaluations (HEEs) of vaccines are commonly con-
sidered during immunization introduction decision-making processes in most 
industrialized countries. Despite the availability of guidelines advocating more 
standardization for such HEEs, there are still several infection/immunization-spe-
cific particularities that are debated in the scientific community. An international 
expert-workshop was convened to identify good practices for (i) how to conduct 
HEEs of vaccines and (ii) how to consider results of HEE in vaccine introduction 
decision-making. MethOds: A systematic literature search was conducted to 
identify prevailing opinions and remaining issues of HEE in vaccination. Twenty-
two experts in the field of health economics and immunization decision-making 
were invited to a workshop and were asked to answer a survey-questionnaire 
based on the systematic literature search beforehand to inform the prepara-
tion of group work sessions (GWS). In GWS, issues focusing on ‘mathematical 
modeling’, ‘health economics’, and ‘decision-making’ were discussed and sum-
marized. Results: The GWS (based on systematic literature search) included 
topics such as cost-components, quality of life (QoL), discounting, and perspec-
tives leading to suggestions such as including caregiver QoL impact and applying 
decreasing time-related discount rates. Since vaccination often causes indirect 
effects, the use of dynamic models is required and exceptions should be justi-
fied. In order to facilitate transparent decision-making, the results of HEE should 
present parameter and methodological uncertainty as well as cumulative and 
time-specific figures. The majority of countries in Europe use results from HEEs 
in an informal judgment-process without willingness to pay (WTP) threshold. The 
expert-group emphasized that transparency should be maximized in decision-
making process. cOnclusiOns: The deliberations led to suggestions on several 
HEE issues. However, vaccines not always need to be considered differently in HEE 
since other interventions might share similar characteristics. Transparency in the 
conduct and presentation of HEE, and subsequent decision-making is essential, 
especially in the absence of explicit WTP thresholds.
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Objectives: To apply in practise an MCDA framework for the value assessment of 
a set of therapeutic options in regards to an oncology indication through an HTA 
simulation exercise. MethOds: Using MCDA principles, past research outcomes 
and the clinical and economic literature, a disease specific value tree was con-
structed incorporating the values concerned as criteria. The alternative options 
were scored against the criteria through the development of value functions, 
weights were assigned to the criteria using a swing method, scores and weights 
were aggregated using a linear additive model, and sensitivity analysis of the results 
was conducted. All the stages were informed by extensive stakeholder engage-
ment through their participation at a decision conference workshop. Results: 
Value parameters considered included burden of illness, therapeutic, safety, inno-
vation and socioeconomic criteria. Overall value scores were produced reflecting 
the performance of the options against the criteria while considering their relative 
importance. Hypothetical payer’s resource allocation decisions on the coverage of 
the options were made on “value for money” grounds through the use of “cost-per-
unit of value” that was derived by incorporating purchasing costs. cOnclusiOns: 
MCDA possesses the prerequisites of a value based assessment methodological 
framework. The multiplicity of criteria that can be incorporated to assess value, 
the weights that can be applied to the criteria, and the stakeholders’ involvement 
